On July 20, 2021, Erasca, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an IPO price of $16.00 per share.

The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, were $345.0 million. Erasca’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “ERAS.”

A Wilson Sonsini team including Deborah Smith, Céline Bonnefous, Matt Wheeler, and Mike Hostetler​ advised Erasca on IP matters related to the transaction.

For more information, please see Erasca's press release.